MedTrace Logo

Observation of Bevacizumab Plus Front-line Chemotherapy in Patients With Ovarian Cancer

NCT01982500 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2017-08-09

No results posted yet for this study

Summary

Investigators propose to assess,the safety and tolerability profile (number of participants with adverse events) of bevacizumab (Avastin) when added to chemotherapy as front-line treatment of epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma

Conditions

Sponsors & Collaborators

  • Hellenic Oncology Research Group

    lead OTHER

Principal Investigators

  • Antonia Kalykaki, MD · Hellenic Oncology Research Group

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2016-10-31
Completion
2017-07-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01982500 on ClinicalTrials.gov